Patient Characteristics and Disease Modifying Therapy use in Patients with Late Onset Multiple Sclerosis: A 30-year Retrospective Review

被引：0
|
作者：
Ahmad, S. [1 ]
Perez-Giraldo, G. [2 ]
Caldito, N. Gonzalez [2 ]
Grebenciucova, E. [2 ]
Balabanov, R. [2 ]
Cohen, B. [2 ]
Graham, E. L. [2 ]
机构：
[1] Univ Nevada, Kirk Kerkorian Sch Med, Las Vegas, NV USA
[2] Northwestern Univ, Dept Neurol Div Multiple Sclerosis & neuroimmunol, Chicago, IL USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P472
引用
收藏
页码：236 / 236
页数：1
相关论文
共 50 条
  • [41] Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis
    Sorensen, Per Soelberg
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2011, 311 : S29 - S34
  • [42] Factors Affecting the Adherence to Disease-Modifying Therapy in Patients With Multiple Sclerosis
    Erbay, Oznur
    Yesilbalkan, Oznur Usta
    Yuceyar, Nur
    JOURNAL OF NEUROSCIENCE NURSING, 2018, 50 (05) : 291 - 297
  • [43] Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis
    F. Schweitzer
    S. Laurent
    G. R. Fink
    Michael H. Barnett
    H. P. Hartung
    C. Warnke
    Journal of Neurology, 2021, 268 : 2379 - 2389
  • [44] Disease Modifying Therapy Discontinuation in Patients with Multiple Sclerosis Over Age 60
    Hua, Le H.
    Fan, Huijun
    Conway, Devon
    Kinzy, Tyler G.
    Thompson, Nicolas
    NEUROLOGY, 2017, 88
  • [45] Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis
    Schweitzer, F.
    Laurent, S.
    Fink, G. R.
    Barnett, Michael H.
    Hartung, H. P.
    Warnke, C.
    JOURNAL OF NEUROLOGY, 2021, 268 (07) : 2379 - 2389
  • [46] Use of diagnostic tests and procedures for disease-modifying therapy users and non-disease-modifying therapy users with multiple sclerosis
    Nair, Kavita V.
    Corboy, John
    Kahler, Kristijan
    Allen, Richard Read
    Ghushcyan, Vahram
    McQueen, Robert Brett
    Bainbridge, Jacci
    Dastani, Homa
    Mody-Patel, Nikita
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2011, 11 (06) : 787 - 798
  • [47] Population characteristics may contribute to the success or failure of disease modifying therapy in multiple sclerosis
    Wakerley, B.
    Jacob, A.
    Ramtahal, J.
    Rashid, S.
    Polito, B.
    Chataway, J.
    Young, C.
    Boggild, M.
    Malik, O.
    Nicholas, R.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2006, 77 (12): : 1389 - 1389
  • [48] The prevalence and characteristics of epilepsy in patients with relapsing-remitting multiple sclerosis treated with disease-modifying therapy
    Kolcava, J.
    Kocica, J.
    Stourac, P.
    Bednarik, J.
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2020, 83 (04) : 424 - 427
  • [49] PRIOR DISEASE-MODIFYING DRUG USE AMONG PATIENTS WITH MULTIPLE SCLEROSIS
    Phillips, A. L.
    Kozma, C. M.
    Lorenzo, R.
    Locklear, J.
    VALUE IN HEALTH, 2014, 17 (03) : A67 - A67
  • [50] Late Onset Multiple Sclerosis Patients Tend to Have Faster Disease Progression
    Alroughani, Raed
    Akhtar, Saeed
    Ahmed, Samar
    Al-Hashel, Jasem
    NEUROLOGY, 2016, 86
12345